Oriza Seed Venture Capital Co-leads $150M Series C Round In Biopharmaceutical Firm Ascentage Pharma

Ascentage Pharma, a Chinese clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancer and other diseases, announced that it has raised a US$150 million series C round co-led by YuanMing Prudence Fund and Oriza Seed Venture Capital, as well as new investor Teng Yue Partners.

CITIC Capital Proposes To Acquire China Biologic Products Holdings For $3.65B

A unit of Chinese investment firm CITIC Capital Holdings Ltd. has offered to buy NASDAQ-listed biotech firm China Biologic Products Holdings, Inc. for US$3.65 billion, according to a security filing by CITIC. The unit, CCRE, offered US$110 in cash for each share for the company. With 33.2 million shares outstanding, the transaction is worth around US$3.65 billion. With the Hong Kong Stock Exchange and Chinese domestic regulators implementing drastic changes to IPO policies to attract the so-called "new economy" companies …

WuXi Biologics To Invest $60M For Its First Manufacturing Facility In United States

WuXi Biologics (2269.HK), an open-access biologics technology company based in China, is to invest US$60 million and hire approximately 150 employees to establish a biologics clinical and commercial manufacturing facility in Worcester, Massachusetts in the United States. The facility will be WuXi Biologics’ 11th global drug substance manufacturing facility, the firm said today in an announcement.